Patient 1ref.3 Patient 2ref.3 Patient 3ref.3 Patient 4ref.3 Patient 5ref.4 Patient 6ref.4 Patient 7ref.4 Patient 8ref.4 Patient 9ref.4 Present patient
age/sex 24/M 37/F 33/F 11/M 66/F 62/M 50/F 50/M 46/M 65/F
disease duration (years) 12 12 4 8 3 3 5 1 2 7
clinical course relapsing relapsing relapsing relapsing relapsing relapsing relapsing relapsing relapsing relapsing
number of relapses 45 10 7 15 5 4 7 4 9 14
paresthesia - - - - finger - - finger finger -
CSF proteins (mg/dl) 123 60 70 96 42 86 98 113 145 175
sensory conduction velocity                    
sural nerve (m/sec) 44 54 43 52 39.4*a 42.3*a 46.2 52.6 42.7 48.6
other sensory nerves normal normal normal normal normal normal normal normal normal normal
sural nerve biopsy normal normal normal - mild abnormal mild abnormal - - - mild abnormal
Response to therapies                    
corticosteroids (ST) No No No No No No No No No No
IVIG Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
plasma exchange (PE) Yes Yes - Yes - - done*b - - -
cyclosporin A - - - No - - - done*b - No
cyclophosphamide - - - - - - - - done*b No
azathioprine Yes No No No - - - - done*b -
interferon alpha - Yes - Yes - - - - - -
Outcome                    
entered remission Yes Yes Yes Yes Yes Yes Yes No No Yes
therapy duringĀ  remission azathioprine, PE interferon alpha IVIG - ST - ST ST ST ST
remission periods (years) 3 1 1 7 1.8 1.5 1.3 - - 4
CSF: cerebrospinal fluid, IVIG: intravenous immunoglobulin, M: male, F: female
*a: authors suggested that sensory nerve conduction slowing was caused by diabetes mellitus.
*b: the therapy was performed, but the effectiveness was not mentioned.
Table 1: Clinical features of reported patients with motor-dominant chronic inflammatory demyelinating polyneuropathy.